112334-43-7

Basic information

• Product Name: 2-Pyridinemethanol, 4,5-bis(phenylmethoxy)-
• CAS NO: 112334-43-7
• Molecular Formula: C20H19NO3
• Molecular Weight: 321.376
• Mol File: 112334-43-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Pyridinemethanol, 4,5-bis(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinemethanol, 4,5-bis(phenylmethoxy)-(112334-43-7)
• EPA Substance Registry System: 2-Pyridinemethanol, 4,5-bis(phenylmethoxy)-(112334-43-7)

Safety Data

• Hazardous Substances Data: 112334-43-7(Hazardous Substances Data)

Upstream product

• 59281-14-0 5-benzyloxy-4-hydroxy-2-hydroxymethylpyridine 
• 100-44-7 benzyl chloride 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 59281-14-0 5-benzyloxy-2-hydroxymethyl-1H-pyridin-4-one 
• 112334-42-6 benzyl 4,5-bis(benzyloxy)picolinate 

Relevant articles and documents

Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections

Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines

Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula STR1